Figure 4.
Activation of ERβ induces the proliferative capacity and inhibits the adipogenic differentiation of TDSCs. (A‐D,J) Immunofluorescence of PCNA and statistic analysis revealed more numbers of PCNA‐positive TSCs with the treatment of LY3201 at the dose of 1 × 10−7 mol/L versus control, but no difference with other concentrations. (E‐H,K) Immunofluorescence of BrdU and statistic analysis revealed more numbers of BrdU‐positive TSCs with the treatment of LY3201 at the dose of 1 × 10−7 mol/L versus control, but no difference with other concentrations. I, CCK‐8 assay revealed the treatment of LY3201 at the dose of 1 × 10−7 mol/L for 48 h promoted proliferation of TSCs, but no difference with other concentrations for other periods. (L‐Q) Oil Red O staining and statistic analysis revealed inhibition of adipogenic differentiation of TDSCs by 1 × 10−7 mol/L LY3201, but no significant difference with other concentrations. (R,S) qRT‐PCR revealed down‐regulated mRNA levels of PPARγ and FABP4 by 1 × 10−7 mol/L LY3201, but no significant difference with other concentrations. Data are represented as mean ± SEM (n = 5), *P < .05, ***P < .001. Scale Bars: 100 μm